Suppr超能文献

肝细胞癌一级预防中的肥胖管理

Obesity Management in the Primary Prevention of Hepatocellular Carcinoma.

作者信息

Zunica Elizabeth R M, Heintz Elizabeth C, Axelrod Christopher L, Kirwan John P

机构信息

Integrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70808, USA.

出版信息

Cancers (Basel). 2022 Aug 22;14(16):4051. doi: 10.3390/cancers14164051.

Abstract

Hepatocellular carcinoma (HCC) is the most frequent primary hepatic malignancy and a leading cause of cancer-related death globally. HCC is associated with an indolent clinical presentation, resulting in frequent advanced stage diagnoses where surgical resection or transplant therapies are not an option and medical therapies are largely ineffective at improving survival. As such, there is a critical need to identify and enhance primary prevention strategies to mitigate HCC-related morbidity and mortality. Obesity is an independent risk factor for the onset and progression of HCC. Furthermore, obesity is a leading cause of nonalcoholic steatohepatitis (NASH), the fasting growing etiological factor of HCC. Herein, we review evolving clinical and mechanistic associations between obesity and hepatocarcinogenesis with an emphasis on the therapeutic efficacy of prevailing lifestyle/behavioral, medical, and surgical treatment strategies for weight reduction and NASH reversal.

摘要

肝细胞癌(HCC)是最常见的原发性肝脏恶性肿瘤,也是全球癌症相关死亡的主要原因。HCC的临床表现较为隐匿,导致晚期诊断频繁,此时手术切除或移植治疗并非选择,而药物治疗在提高生存率方面大多无效。因此,迫切需要确定并加强一级预防策略,以减轻与HCC相关的发病率和死亡率。肥胖是HCC发病和进展的独立危险因素。此外,肥胖是非酒精性脂肪性肝炎(NASH)的主要原因,而NASH是HCC发病率增长最快的病因。在此,我们综述肥胖与肝癌发生之间不断演变的临床和机制关联,重点关注当前生活方式/行为、药物和手术治疗策略在减轻体重和逆转NASH方面的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/675b/9406638/7c293597a9cf/cancers-14-04051-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验